Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Next Previous
Search
Trial Profile

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Cetuximab (Primary) ; Crizotinib (Primary) ; Dasatinib (Primary) ; Encorafenib (Primary) ; Everolimus (Primary) ; Gemcitabine (Primary) ; Idelalisib (Primary) ; Larotrectinib (Primary) ; Methotrexate (Primary) ; Palbociclib (Primary) ; Panobinostat (Primary) ; Pembrolizumab (Primary) ; Pertuzumab (Primary) ; Talazoparib (Primary) ; Trastuzumab (Primary) ; Venetoclax (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EVIDENT

    • Most Recent Events

    • 21 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top